Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-Letters: Submit a response to the article
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (47)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Levy, J. H.
Right arrow Articles by McCall, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Levy, J. H.
Right arrow Articles by McCall, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

British Journal of Anaesthesia, 2000, Vol. 85, No. 6 844-849
© 2000 The Board of Management and Trustees of the British Journal of Anaesthesia

Weal and flare responses to intradermal rocuronium and cisatracurium in humans{dagger}

J. H. Levy1, M. Gottge1, F. Szlam1, R. Zaffer1 and C. McCall2

1Department of Anesthesiology, Emory University Hospital, 1364 Clifton Road, NE, Atlanta, GA 30322, USA. 2Department of Dermatology, Emory University Hospital, 1364 Clifton Road, NE, Atlanta, GA 30322, USA.*Corresponding author

Thirty volunteers underwent intradermal skin testing with increasing concentrations of rocuronium and cisatracurium to evaluate weal and flare responses, and whether either agent would cause mast cell degranulation and sensitization upon re-exposure. We found that intradermal injection of rocuronium and cisatracurium at concentrations >10–4 M resulted in positive weal (>8 mm) responses, and positive flare responses at >10–4 and >10–5 M respectively. Only cisatracurium caused mild to moderate mast cell degranulation, and neither drug caused significant in vitro histamine release from whole blood collected from study subjects 4 weeks after skin testing. Skin testing with rocuronium and cisatracurium should be performed at concentrations <10–4 and <10–5 M respectively to avoid false-positive responses. The ability of these agents to produce positive weal and flare responses at relatively low concentrations may explain the high incidence of potential reactions reported.

Br J Anaesth 2000; 85: 844–9


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Anesth. Analg.Home page
P. Dewachter and C. Mouton-Faivre
Skin Testing Performed in Individuals Cannot be Compared with Responses from Anaphylactic Patients
Anesth. Analg., October 1, 2008; 107(4): 1441 - 1441.
[Full Text] [PDF]

Home page
 Anesth. Analg.Home page
J. H. Levy
Skin Testing Performed in Individuals Cannot be Compared with Responses from Anaphylactic Patients
Anesth. Analg., October 1, 2008; 107(4): 1441 - 1441.
[Full Text] [PDF]

Home page
 Anesth. Analg.Home page
J. H. Levy and N. F. Adkinson Jr
Anaphylaxis During Cardiac Surgery: Implications for Clinicians
Anesth. Analg., February 1, 2008; 106(2): 392 - 403.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
P. M. Mertes, M. C. Laxenaire, J. M. Malinovsky, E. Florvaag, and D. A. Moneret-Vautrin
Skin Sensitivity to Rocuronium and Vecuronium: Prick-Tests Are Not Intradermal Test
Anesth. Analg., May 1, 2005; 100(5): 1539 - 1539.
[Full Text] [PDF]

Home page
 Anesth. Analg.Home page
G. Dhonneur
Skin Sensitivity to Rocuronium and Vecuronium: Prick-Tests Are Not Intradermal Test
Anesth. Analg., May 1, 2005; 100(5): 1539 - 1540.
[Full Text] [PDF]

Home page
 Anesth. Analg.Home page
M. Fisher and G. Dhonneur
Prick Testing for Neuromuscular Blocking Drugs * Response
Anesth. Analg., December 1, 2004; 99(6): 1880 - 1881.
[Full Text] [PDF]

Home page
 Br J AnaesthHome page
A. D. Axon and J. M. Hunter
Editorial III: Anaphylaxis and anaesthesia--all clear now?
Br. J. Anaesth., October 1, 2004; 93(4): 501 - 504.
[Full Text] [PDF]

Home page
 Anesth. Analg.Home page
J. H. Levy
Anaphylactic Reactions to Neuromuscular Blocking Drugs: Are We Making the Correct Diagnosis?
Anesth. Analg., April 1, 2004; 98(4): 881 - 882.
[Full Text] [PDF]

Home page
 Anesth. Analg.Home page
G. Dhonneur, X. Combes, D. Chassard, and J. C. Merle
Skin Sensitivity to Rocuronium and Vecuronium: A Randomized Controlled Prick-Testing Study in Healthy Volunteers
Anesth. Analg., April 1, 2004; 98(4): 986 - 989.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
D. L. Hepner and M. C. Castells
Anaphylaxis During the Perioperative Period
Anesth. Analg., November 1, 2003; 97(5): 1381 - 1395.
[Abstract] [Full Text] [PDF]

Home page
 Br J AnaesthHome page
C. Baillard, A. M. Korinek, V. Galanton, Y. Le Manach, P. Larmignat, M. Cupa, and C. M. Samama
Anaphylaxis to rocuronium
Br. J. Anaesth., April 1, 2002; 88(4): 600 - 602.
[Abstract] [Full Text] [PDF]

Home page
 Br J AnaesthHome page
E. W. Moore and J. M. Hunter
The new neuromuscular blocking agents: do they offer any advantages?
Br. J. Anaesth., December 1, 2001; 87(6): 912 - 925.
[Abstract] [Full Text] [PDF]

Home page
 Br J AnaesthHome page
M. C. Laxenaire, P. M. Mertes, and Groupe d'Etudes des Reactions Anaphylactoides Pera
Anaphylaxis during anaesthesia. Results of a two-year survey in France
Br. J. Anaesth., October 1, 2001; 87(4): 549 - 558.
[Abstract] [Full Text] [PDF]

Home page
 Br J AnaesthHome page
M. Rose and M. Fisher
Rocuronium: high risk for anaphylaxis?
Br. J. Anaesth., May 1, 2001; 86(5): 678 - 682.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.